DK1913000T3 - Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese - Google Patents
Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og synteseInfo
- Publication number
- DK1913000T3 DK1913000T3 DK06779900.7T DK06779900T DK1913000T3 DK 1913000 T3 DK1913000 T3 DK 1913000T3 DK 06779900 T DK06779900 T DK 06779900T DK 1913000 T3 DK1913000 T3 DK 1913000T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrrolo
- intermediates
- synthesis
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70401105P | 2005-07-29 | 2005-07-29 | |
PCT/IB2006/002048 WO2007012953A2 (en) | 2005-07-29 | 2006-07-17 | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1913000T3 true DK1913000T3 (da) | 2012-03-12 |
Family
ID=36950230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06779900.7T DK1913000T3 (da) | 2005-07-29 | 2006-07-17 | Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese |
Country Status (24)
Country | Link |
---|---|
US (2) | US8232394B2 (da) |
EP (1) | EP1913000B1 (da) |
JP (1) | JP4052523B2 (da) |
KR (1) | KR100987870B1 (da) |
CN (1) | CN101233138A (da) |
AR (1) | AR056004A1 (da) |
AT (1) | ATE540952T1 (da) |
AU (1) | AU2006273762A1 (da) |
BR (1) | BRPI0613876A2 (da) |
CA (1) | CA2614907C (da) |
CY (1) | CY1112319T1 (da) |
DK (1) | DK1913000T3 (da) |
ES (1) | ES2377771T3 (da) |
IL (1) | IL188372A0 (da) |
MX (1) | MX2008001334A (da) |
NZ (1) | NZ565363A (da) |
PL (1) | PL1913000T3 (da) |
PT (1) | PT1913000E (da) |
RU (1) | RU2384583C2 (da) |
SG (1) | SG170783A1 (da) |
SI (1) | SI1913000T1 (da) |
TW (1) | TWI319402B (da) |
WO (1) | WO2007012953A2 (da) |
ZA (1) | ZA200800284B (da) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2445098C2 (ru) | 2007-07-11 | 2012-03-20 | Пфайзер Инк. | Фармацевтические композиции и способы лечения сухих кератитов |
ES2552805T3 (es) | 2009-04-20 | 2015-12-02 | Auspex Pharmaceuticals, Llc | Inhibidores piperidínicos de la cinasa Janus 3 |
CA2773182A1 (en) * | 2009-09-10 | 2011-03-17 | F. Hoffmann-La Roche Ag | Inhibitors of jak |
WO2011045702A1 (en) | 2009-10-15 | 2011-04-21 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
CA2782720A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
CN102712640A (zh) | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
US20120309776A1 (en) | 2010-02-05 | 2012-12-06 | Pfitzer Inc. | Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors |
CA2830463A1 (en) | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Pharmaceutical composition comprising tofacitinib and a penetration enhancer |
WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
EP3170827A1 (en) * | 2011-12-15 | 2017-05-24 | ratiopharm GmbH | Tofacitinib mono-oxalate salt |
MX349943B (es) * | 2012-07-17 | 2017-08-21 | Glaxosmithkline Ip No 2 Ltd | Indolcarbonitrilos como moduladores selectivos del receptor de androgeno. |
WO2014016338A1 (en) | 2012-07-25 | 2014-01-30 | Lek Pharmaceuticals D.D. | New synthetic route for the preparation of 3-amino-piperidine compounds |
CN102875555A (zh) * | 2012-09-27 | 2013-01-16 | 同济大学 | 一种JAK抑制剂Tofacitinib的合成方法 |
CN104955803B (zh) * | 2012-11-30 | 2017-11-28 | 斯洛文尼亚莱柯制药股份有限公司 | 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物 |
WO2014097150A1 (en) * | 2012-12-17 | 2014-06-26 | Ranbaxy Laboratories Limited | Process for the preparation of tofacitinib and intermediates thereof |
WO2014102826A1 (en) * | 2012-12-28 | 2014-07-03 | Glenmark Pharmaceuticals Limited; | The present invention relates to process for the preparation of tofacitinib and intermediates thereof. |
CN103073552B (zh) * | 2013-02-05 | 2015-08-12 | 华润赛科药业有限责任公司 | 一种无定型枸橼酸托法替尼的制备方法 |
NZ710411A (en) | 2013-02-22 | 2017-11-24 | Pfizer | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
WO2014174073A1 (en) | 2013-04-26 | 2014-10-30 | Sandoz Ag | Sustained release formulations of tofacitinib |
CN104447752A (zh) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种托法替尼水合物及其制备方法 |
CN104447751A (zh) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种托法替尼化合物 |
CN104292231B (zh) * | 2013-09-17 | 2016-11-30 | 广东东阳光药业有限公司 | 一种枸橼酸托法替尼的制备方法 |
CN105873931B (zh) * | 2013-10-08 | 2018-10-16 | 广东东阳光药业有限公司 | 托法替布柠檬酸盐 |
CN103819474A (zh) * | 2013-11-04 | 2014-05-28 | 湖南华腾制药有限公司 | 一种托法替尼的制备方法 |
MA39092B1 (fr) | 2013-12-05 | 2018-09-28 | Pfizer | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides |
PL2994454T3 (pl) | 2013-12-09 | 2019-09-30 | Unichem Laboratories Limited | Ulepszony sposób wytwarzania (3R,4R)-(1-benzylo-4-metylopiperydyn-3-ylo)metyloaminy |
CN104774206A (zh) * | 2014-01-14 | 2015-07-15 | 江苏柯菲平医药股份有限公司 | 制备枸橼酸托伐替尼晶型a的新方法 |
CN103755624B (zh) * | 2014-01-20 | 2018-10-09 | 上海博氏医药科技有限公司 | 一种哌啶衍生物的合成方法 |
CN105085527A (zh) * | 2014-05-20 | 2015-11-25 | 南京海纳医药科技有限公司 | 高效合成托法替尼的方法 |
EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
JP6612331B2 (ja) * | 2014-09-15 | 2019-11-27 | リューゲン ホールディングス (ケイマン) リミテッド | Nr2b nmda受容体アンタゴニストとしてのピロロピリミジン誘導体 |
CN104530053A (zh) * | 2014-12-08 | 2015-04-22 | 合肥远志医药科技开发有限公司 | 一种药用晶型枸橼酸托法替尼的制备方法 |
CN104530055A (zh) * | 2014-12-23 | 2015-04-22 | 南京艾德凯腾生物医药有限责任公司 | 枸橼酸托法替布的制备方法 |
CN105837574B (zh) * | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
CN104710346B (zh) * | 2015-02-15 | 2017-04-12 | 江苏苏利精细化工股份有限公司 | 一种合成顺式‑1‑苄基‑3‑甲氨基‑4‑甲基‑哌啶的方法 |
US20180010158A1 (en) * | 2015-02-20 | 2018-01-11 | Sun Pharmaceutical Industries Limited | A process for the preparation of tofacitinib citrate |
CN104761556B (zh) * | 2015-03-21 | 2017-06-23 | 河北国龙制药有限公司 | 托法替布中间体杂质、托法替布杂质及其合成方法,以及托法替布的质量监控方法 |
CN104860872A (zh) * | 2015-03-27 | 2015-08-26 | 天津药物研究院有限公司 | 一种双-(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺l-二对甲基苯甲酰酒石酸盐的合成方法 |
EP3078665A1 (en) | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
CN104788461A (zh) * | 2015-04-30 | 2015-07-22 | 南京臣功制药股份有限公司 | 一种适合枸橼酸托法替尼工业化的生产方法 |
ES2928757T3 (es) | 2015-05-01 | 2022-11-22 | Pfizer | Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa |
CN104987339A (zh) * | 2015-07-29 | 2015-10-21 | 张燕梅 | 一种枸橼酸托法替布的合成方法 |
AU2017221193B2 (en) | 2016-02-16 | 2019-03-14 | Zoetis Services Llc | Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds |
CN105732641A (zh) * | 2016-03-28 | 2016-07-06 | 南通常佑药业科技有限公司 | 一种JAKs抑制剂药物托法替尼的制备方法 |
CN105884781B (zh) * | 2016-04-18 | 2018-04-20 | 山东罗欣药业集团股份有限公司 | 一种枸橼酸托法替布的制备方法 |
CN106146517B (zh) * | 2016-06-20 | 2018-08-28 | 山东大学 | 一种枸橼酸托法替尼的合成方法 |
CN106188064A (zh) * | 2016-07-07 | 2016-12-07 | 国药集团容生制药有限公司 | 一种N‑甲基‑N‑((3R,4R)‑4‑甲基吡啶‑3‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑4‑胺的制备方法 |
CN105949204A (zh) * | 2016-07-25 | 2016-09-21 | 国药集团容生制药有限公司 | 一种N-((3R,4R)-1-苄基-4-甲基吡啶-3-基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺的制备方法 |
EP3421455B1 (en) | 2017-06-29 | 2019-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib |
CN109293682A (zh) * | 2017-07-25 | 2019-02-01 | 重庆医药工业研究院有限责任公司 | 一种托法替布杂质及其制备方法 |
CN107698595A (zh) * | 2017-09-23 | 2018-02-16 | 江苏正大清江制药有限公司 | 一种枸橼酸托法替布有关物质的制备方法 |
CN107793418B (zh) * | 2017-10-24 | 2020-08-04 | 扬子江药业集团有限公司 | 一种枸橼酸托法替布的工业化生产方法 |
CN108640923A (zh) * | 2018-07-09 | 2018-10-12 | 湖南天地恒制药有限公司 | 一种托法替布关键中间体的制备方法 |
CN108822112B (zh) * | 2018-08-13 | 2019-12-20 | 山东罗欣药业集团恒欣药业有限公司 | 一种托法替尼化合物的制备方法 |
CN109608468B (zh) * | 2018-12-29 | 2020-09-29 | 成都倍特药业股份有限公司 | 一种枸橼酸托法替布杂质及其合成方法和用途 |
KR102131107B1 (ko) * | 2019-01-15 | 2020-07-07 | 주식회사 다산제약 | 3-아미노-피페리딘 화합물의 신규한 제조 방법 |
CN109503462B (zh) * | 2019-01-21 | 2022-03-25 | 内蒙古京东药业有限公司 | 托法替布中间体(3r,4r)-n,4-二甲基-1-苄基-3-哌啶胺的合成方法 |
CN109761884B (zh) * | 2019-01-30 | 2020-03-31 | 湖北扬信医药科技有限公司 | 一种手性胺b的制备方法及其应用 |
US20220153743A1 (en) | 2019-03-13 | 2022-05-19 | Intas Pharmaceuticals Ltd. | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof |
CN113993585A (zh) | 2019-03-27 | 2022-01-28 | 英矽智能科技知识产权有限公司 | 双环jak抑制剂及其用途 |
WO2020204647A1 (en) * | 2019-04-05 | 2020-10-08 | Yuhan Corporation | Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same |
CN110724146B (zh) * | 2019-11-04 | 2022-03-11 | 四川大学 | 一种枸橼酸托法替布的制备方法 |
CA3192099A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
AU2021329301A1 (en) | 2020-08-18 | 2023-04-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
CN112679508B (zh) * | 2021-03-09 | 2021-08-10 | 正大天晴药业集团南京顺欣制药有限公司 | 一种托法替布中间体的制备方法 |
CN113248509B (zh) * | 2021-05-17 | 2022-10-04 | 上海中西三维药业有限公司 | 一种枸橼酸托法替布中间体的制备方法 |
CN113735860A (zh) * | 2021-08-26 | 2021-12-03 | 安徽鼎旺医药有限公司 | 一种枸橼酸托法替布的合成方法 |
CN114685515A (zh) * | 2022-03-15 | 2022-07-01 | 上海蓝乐鸟实业有限公司 | 一种托法替尼的制备方法 |
CN114835714A (zh) * | 2022-04-01 | 2022-08-02 | 上海蓝乐鸟实业有限公司 | 一种托法替尼的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0710877A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | 4―ヘテロアリサイクリック―ピロロ[2,3―d]ピリミジン |
AP1905A (en) | 1999-12-10 | 2008-10-20 | Pfizer Prod Inc | Pyrrolo[2,3-d] Pyrimidine Compounds. |
US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
AP2003002929A0 (en) | 2001-06-23 | 2003-12-31 | Aventis Pharma Inc | Pyrrolopyrimidines as protein kinase inhibitors |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
US20040012627A1 (en) | 2002-07-17 | 2004-01-22 | Sany Zakharia | Configurable browser for adapting content to diverse display types |
EP1551410A2 (en) * | 2002-09-06 | 2005-07-13 | Smithkline Beecham Corporation | Novel compounds |
KR100742012B1 (ko) | 2002-11-21 | 2007-07-23 | 화이자 프로덕츠 인코포레이티드 | 3-아미노-피페리딘 유도체 및 그의 제조 방법 |
AU2004233897A1 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
-
2006
- 2006-07-17 PT PT06779900T patent/PT1913000E/pt unknown
- 2006-07-17 PL PL06779900T patent/PL1913000T3/pl unknown
- 2006-07-17 DK DK06779900.7T patent/DK1913000T3/da active
- 2006-07-17 CN CNA2006800279013A patent/CN101233138A/zh active Pending
- 2006-07-17 WO PCT/IB2006/002048 patent/WO2007012953A2/en active Application Filing
- 2006-07-17 SI SI200631245T patent/SI1913000T1/sl unknown
- 2006-07-17 US US11/996,899 patent/US8232394B2/en active Active
- 2006-07-17 MX MX2008001334A patent/MX2008001334A/es active IP Right Grant
- 2006-07-17 AU AU2006273762A patent/AU2006273762A1/en not_active Abandoned
- 2006-07-17 CA CA2614907A patent/CA2614907C/en active Active
- 2006-07-17 EP EP06779900A patent/EP1913000B1/en active Active
- 2006-07-17 ES ES06779900T patent/ES2377771T3/es active Active
- 2006-07-17 NZ NZ565363A patent/NZ565363A/en not_active IP Right Cessation
- 2006-07-17 BR BRPI0613876-4A patent/BRPI0613876A2/pt not_active IP Right Cessation
- 2006-07-17 RU RU2008103279/04A patent/RU2384583C2/ru not_active IP Right Cessation
- 2006-07-17 SG SG201102177-1A patent/SG170783A1/en unknown
- 2006-07-17 KR KR1020087002240A patent/KR100987870B1/ko not_active IP Right Cessation
- 2006-07-17 AT AT06779900T patent/ATE540952T1/de active
- 2006-07-27 AR ARP060103254A patent/AR056004A1/es unknown
- 2006-07-28 JP JP2006206218A patent/JP4052523B2/ja active Active
- 2006-07-28 TW TW095127592A patent/TWI319402B/zh not_active IP Right Cessation
-
2007
- 2007-12-24 IL IL188372A patent/IL188372A0/en unknown
-
2008
- 2008-01-09 ZA ZA200800284A patent/ZA200800284B/xx unknown
-
2012
- 2012-02-06 CY CY20121100122T patent/CY1112319T1/el unknown
- 2012-06-20 US US13/528,099 patent/US8309716B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2008001334A (es) | 2008-03-24 |
CY1112319T1 (el) | 2015-12-09 |
PL1913000T3 (pl) | 2012-05-31 |
EP1913000B1 (en) | 2012-01-11 |
TW200745119A (en) | 2007-12-16 |
ES2377771T3 (es) | 2012-03-30 |
BRPI0613876A2 (pt) | 2011-02-15 |
NZ565363A (en) | 2010-03-26 |
IL188372A0 (en) | 2008-04-13 |
RU2008103279A (ru) | 2009-08-10 |
ZA200800284B (en) | 2008-12-31 |
SG170783A1 (en) | 2011-05-30 |
AU2006273762A1 (en) | 2007-02-01 |
CA2614907C (en) | 2012-02-28 |
WO2007012953A3 (en) | 2007-05-18 |
KR100987870B1 (ko) | 2010-10-13 |
KR20080031338A (ko) | 2008-04-08 |
SI1913000T1 (sl) | 2012-02-29 |
US8309716B2 (en) | 2012-11-13 |
CN101233138A (zh) | 2008-07-30 |
CA2614907A1 (en) | 2007-02-01 |
JP4052523B2 (ja) | 2008-02-27 |
RU2384583C2 (ru) | 2010-03-20 |
EP1913000A2 (en) | 2008-04-23 |
ATE540952T1 (de) | 2012-01-15 |
AR056004A1 (es) | 2007-09-12 |
US20120259115A1 (en) | 2012-10-11 |
JP2007039455A (ja) | 2007-02-15 |
TWI319402B (en) | 2010-01-11 |
WO2007012953A2 (en) | 2007-02-01 |
US8232394B2 (en) | 2012-07-31 |
PT1913000E (pt) | 2012-02-28 |
US20110288297A1 (en) | 2011-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1913000T3 (da) | Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese | |
MA28824B1 (fr) | Derives de pyrimidine | |
ATE512960T1 (de) | Pyrimidinderivate | |
HK1120269A1 (en) | Pyrimidine derivatives | |
GB0525080D0 (en) | Pyrimidine derivatives | |
GB0525083D0 (en) | Pyrimidine derivatives | |
GB0415364D0 (en) | Pyrimidine derivatives | |
HK1104553A1 (en) | Pyrimidine derivatives | |
DK1966202T3 (da) | Heteroarylsubstituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-d]pyrimidiner som Januskinaseinhibitorer | |
EP1724267A4 (en) | PYRIMIDINE DERIVATIVE | |
DK1797099T3 (da) | Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser | |
ATE487718T1 (de) | Substituierte bizyklische pyrimidonderivate | |
IL186939A0 (en) | Pyrimidine derivatives and their use as | |
GB0525081D0 (en) | Pyrimidine derivatives | |
SI1869056T1 (sl) | Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati | |
SMP200800029B (it) | 2-ammino-7,8-diidro-6h-pirido[4,3-d]pirimidin-5-oni | |
ATE449080T1 (de) | 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate | |
DK1765844T3 (da) | Purin-nukleotidderivater | |
DK1902054T3 (da) | Pyrido[2,3-d]pyrimidinderivater, fremstilling og terapeutisk anvendelse heraf | |
GB0415367D0 (en) | Pyrimidine derivatives | |
SE0400213D0 (sv) | Diurea Derivatives | |
ZA200804208B (en) | Oxygen linked pyrimidine derivatives |